Welcome to our dedicated page for Hologic SEC filings (Ticker: HOLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Hologic’s SEC reports can feel like reviewing an FDA submission—dense tables on Panther diagnostic assay margins, breast-health imaging upgrades, and goodwill adjustments from Gen-Probe. Add in complex risk factors on regulatory approvals and you have hundreds of pages that busy investors rarely finish. That’s why users search for “Hologic SEC filings explained simply” or “how to read a Hologic annual report 10-K.”
Stock Titan’s AI solves that problem. Our engine converts every Hologic annual report 10-K simplified, each Hologic quarterly earnings report 10-Q filing, and every Hologic 8-K material events explained into plain-language briefs, highlighting FDA milestones, segment revenue swings, and cash-flow drivers. Need real-time alerts? You’ll see Hologic Form 4 insider transactions real-time the moment executives file, plus side-by-side graphs of option grants and share repurchases. From Hologic proxy statement executive compensation details to the next Hologic earnings report filing analysis, every document is updated the second it hits EDGAR.
The result: faster, sharper decisions. Track Hologic insider trading Form 4 transactions to gauge management sentiment, compare operating margins across Diagnostics and Surgical segments without combing through footnotes, and monitor covenant disclosures before debt maturities surface. Whether you’re understanding Hologic SEC documents with AI for a quick thesis check or following Hologic executive stock transactions Form 4 ahead of product launches, Stock Titan gives you complete coverage, AI-powered summaries, and expert context—no more scrolling through 250 pages to find one number.
Schedule 13G/A Amendment No. 5 filing for Enovis Corporation (ENOV) discloses that T. Rowe Price Investment Management, Inc. (TRPIM) beneficially owns 1,202 shares of Enovis common stock as of the event date 30 June 2025. This equates to 0.0 % of the outstanding class, well below the 5 % threshold for significant ownership disclosure.
TRPIM reports sole voting and dispositive power over the entire 1,202-share position, with no shared voting or dispositive power. The firm files under Rule 13d-1(b) in its capacity as a registered investment adviser (IA) and certifies that the shares are held in the ordinary course of business, not to influence control of the issuer. The filing includes the standard disclaimer that submission of the Schedule 13G does not constitute an admission of beneficial ownership.
The document is signed by Vice President Ellen York on 8 July 2025. No other material transactions, financial metrics, or strategic intentions are disclosed.
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
What are the main business segments of Hologic Inc?
How does Hologic generate revenue?
What differentiates Hologic from other companies in the medical technology sector?
What is the significance of Hologic's diagnostics segment?
How does Hologic maintain its competitive position in global markets?
How do Hologic's products benefit patient care?
What markets does Hologic primarily serve?
How has Hologic expanded its product portfolio in recent years?
